What are the recommended anti‑anginal medications and dosing sequence for managing stable angina?

Anti-Anginal Medications for Stable Angina

First-Line Therapy

Start with short-acting nitrates for immediate symptom relief, then initiate either a beta-blocker or calcium channel blocker (CCB) as maintenance therapy based on heart rate, blood pressure, and comorbidities. 1

Immediate Relief

• Short-acting nitrates are the standard for acute angina episodes and should be prescribed to all patients for on-demand use 1

Initial Maintenance Therapy Selection

Choose between beta-blockers and CCBs based on the following clinical parameters:

• Beta-blockers are preferred when:

  • Heart rate >60-70 bpm 1, 2
  • Comorbid heart failure with reduced ejection fraction 2
  • Hypertension (can combine with RAAS blocker or CCB) 2
  • Microvascular angina (combine with RAAS blocker and statin) 2
  • Post-myocardial infarction 1

• Avoid or use beta-blockers cautiously when:

  • Heart rate <50 bpm (contraindicated unless pacemaker present) 2
  • Sick sinus syndrome or AV conduction disorders 1
  • Peripheral artery disease 1
  • Chronic obstructive pulmonary disease 1

• Calcium channel blockers (long-acting dihydropyridines) are preferred when:

  • Beta-blockers are contraindicated or not tolerated 1
  • Low baseline heart rate 1
  • Coronary artery spasm is suspected 1

• Avoid CCBs when:

  • Heart failure with reduced ejection fraction (use with caution) 1

Important caveat: Despite guidelines traditionally favoring beta-blockers and CCBs as "first-line," systematic reviews show no antianginal drug is superior to another in efficacy, and none reduce mortality or myocardial infarction risk 3. The classification is based more on historical precedent than comparative evidence 1, 3.

Combination Therapy (Second Step)

If symptoms persist on monotherapy, combine a beta-blocker with a dihydropyridine CCB (e.g., amlodipine, nifedipine) 1

Critical Drug Interaction Warning:

• Never combine ivabradine with non-dihydropyridine CCBs (verapamil or diltiazem) due to CYP3A4 inhibition 1
• Never combine beta-blockers with non-dihydropyridine CCBs due to excessive heart rate and AV conduction suppression 1

Third-Line Add-On Therapy

When beta-blocker plus dihydropyridine CCB combination fails to control symptoms, add one of the following agents: 1

• Long-acting nitrates (requires nitrate-free interval to prevent tolerance) 1, 4
• Ranolazine - particularly useful when heart rate or blood pressure is low 1
• Trimetazidine - particularly useful when heart rate or blood pressure is low 1
• Ivabradine - only in patients with LV systolic dysfunction; avoid with non-DHP CCBs 1
• Nicorandil - particularly for coronary artery spasm 1

Special Contraindications:

• Nitrates are absolutely contraindicated with:
  • Phosphodiesterase inhibitors (sildenafil, tadalafil, etc.) 1
  • Hypertrophic cardiomyopathy 1

Alternative Initial Therapy

For patients with contraindications or intolerance to both beta-blockers AND CCBs, consider starting with: 1

• Ivabradine
• Nicorandil
• Long-acting nitrates
• Ranolazine
• Trimetazidine

For microvascular angina specifically: Ranolazine or trimetazidine are reasonable first choices 1

For coronary artery spasm specifically: Nicorandil or nitrates are reasonable first choices 1

Evidence Quality Note

The 2024 ESC guidelines 1 provide the most current algorithmic approach, though they acknowledge most recommendations are Class I with Level B or C evidence, reflecting limited high-quality comparative data. Research confirms that all antianginal agents have equivalent efficacy for symptom control, with no mortality benefit demonstrated for any agent 5, 3. The emphasis should be on achieving symptom control while avoiding drug interactions and contraindications based on comorbidities 1.